Genomic variation-guided management in chronic hepatitis C
Journal
Expert Review of Gastroenterology and Hepatology
Journal Volume
6
Journal Issue
4
Pages
497-506
Date Issued
2012
Author(s)
Hsu C.-S.
Abstract
In 2009, several different research groups simultaneously identified the polymorphisms close to IL28B gene as an important predictor of therapeutic response for chronic hepatitis C (CHC) patients receiving interferon-based treatment using approaches of genome-wide association studies. They also found that these genetic variations were strongly associated with the spontaneous viral clearance of hepatitis C virus (HCV) infection. Following these studies, ITPA gene variants were reported to affect ribavirin-induced anemia and therapeutic outcomes of CHC patients. All these lines of evidence usher in a new genomic era for the management of HCV infection. In this article, advances in recent genome-wide association studies regarding HCV infection, and their impacts on the management of CHC patients will be reviewed. In addition, the clinical usefulness of genomic variations on the addition of direct antiviral agents to current standard of care will be discussed. ? 2012 Expert Reviews Ltd.
Subjects
hepatitis C virus; IL28B SNP; individualized therapy; metabolic profiles; pegylated interferon; viral kinetics
SDGs
Other Subjects
alpha interferon; boceprevir; interleukin 28; interleukin 29; major histocompatibility antigen class 1; peginterferon; peginterferon lambda; placebo; ribavirin; telaprevir; vaniprevir; amino acid substitution; antiviral therapy; CD4+ T lymphocyte; CD8+ T lymphocyte; cytokine production; gene; gene linkage disequilibrium; genetic association; genetic variability; genotype; hemolytic anemia; hepatitis C; human; IL28B gene; ITPA gene; liver fibrosis; liver transplantation; missense mutation; natural killer cell; nonhuman; review; seroconversion; single nucleotide polymorphism; unspecified side effect; viral clearance; Antiviral Agents; Genome-Wide Association Study; Genotype; Hepatitis C, Chronic; Humans; Individualized Medicine; Interferon-alpha; Interleukins; Pharmacogenetics; Polyethylene Glycols; Pyrophosphatases; Recombinant Proteins; Ribavirin
Type
review